{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:53:28Z","timestamp":1779317608138,"version":"3.51.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The exact etiology of pruritus in chronic cholestasis is unknown. Pruritus intensity does not correlate with common biochemical indices and there is a lack of biomarkers guiding diagnosis and treatment. We explored profiles of bile acids (BA) and muricholic acids (MCA) as well as autotaxin (ATX) antigen levels as potential circulating biomarkers of pruritus in pediatric patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In 27 pediatric cholestatic patients [autoimmune sclerosing cholangitis (ASC) <jats:italic>n<\/jats:italic> = 20 (with pruritus <jats:italic>n<\/jats:italic> = 6, without pruritus <jats:italic>n<\/jats:italic> = 14); progressive familial intrahepatic cholestasis (PFIC) <jats:italic>n<\/jats:italic> = 7 (with pruritus <jats:italic>n<\/jats:italic> = 5, without pruritus <jats:italic>n<\/jats:italic> = 2)] and 23 age-matched controls pruritus was assessed by a visual analog scale of pruritus (PVAS). We obtained profiles of serum human BA including MCA using a mass-spectrometry assay and ATX antigen levels with a commercial ELISA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PFIC and ASC patients exhibited significantly higher BA-, and MCA levels, than healthy controls, but only PFIC patients showed elevated ATX antigen levels higher [median: 1,650 ng\/ml, interquartile rang (IQR): 776.9\u20133,742] compared to controls (median: 315.9 ng\/ml, IQR: 251.1\u2013417.2; PFIC <jats:italic>p<\/jats:italic> = 0.0003). ASC patients with pruritus showed only a minor increase in total BA (tBA) levels (median: 76.5 \u03bcmol\/L, IQR: 54.7\u2013205), but strikingly higher T-conjugated BA (median: 16.4 \u03bcmol\/L, IQR: 8.9\u201341.4) and total MCA (tMCA) (median: 1.15 \u03bcmol\/L, IQR: 0.77\u20132.44) levels compared to ASC patients without pruritus (tBA median: 24.3 \u03bcmol\/L, IQR: 16.2\u201380.8; <jats:italic>p<\/jats:italic> &amp;lt; 0.0408; T-conjugated BA median: 1.3 \u03bcmol\/L, IQR: 0.8\u20134.9; <jats:italic>p<\/jats:italic> = 0.0023; tMCA median: 0.30 \u03bcmol\/L, IQR: 0.13\u20130.64, <jats:italic>p<\/jats:italic> = 0.0033). BA\/MCA profiles distinctly differed depending on presence\/absence of pruritus. Different from PFIC patients, ATX antigen levels were not significantly elevated in ASC patients with (median: 665.8 ng\/ml, IQR: 357.8\u20131,203) and without pruritus (median: 391.0 ng\/ml, IQR: 283.2\u2013485.6). In ASC patients, tBA, tMCA, and ATX antigen levels did not correlate with pruritus severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite the same underlying disease, pediatric ASC patients with pruritus exhibit significantly altered BA profiles and MCA levels compared to ASC patients without pruritus. ATX antigen levels seem to have little diagnostic or prognostic meaning in ASC patients. An increased ATX activity alone seems not to be causal for pruritus genesis in ASC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p>[<jats:ext-link>www.drks.de<\/jats:ext-link>], identifier [DRKS00026913].<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.903360","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T07:38:25Z","timestamp":1652254705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Covert Surge: Murine Bile Acid Levels Are Associated With Pruritus in Pediatric Autoimmune Sclerosing Cholangitis"],"prefix":"10.3389","volume":"10","author":[{"given":"Katharina","family":"Meinel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doloresz","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antal","family":"Dezsofi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Strini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Greimel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Aguiriano-Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Haidl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Schlagenhauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Jahnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.clinre.2012.04.003","article-title":"Specificities of sclerosing cholangitis in childhood.","volume":"36","author":"Girard","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cld.2018.06.003","article-title":"Progressive familial intrahepatic cholestasis.","volume":"22","author":"Bull","year":"2018","journal-title":"Clin Liver Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cld.2012.03.010","article-title":"Pruritus in chronic cholestatic liver disease.","volume":"16","author":"Bunchorntavakul","year":"2012","journal-title":"Clin Liver Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1046\/j.1365-2036.2003.01458.x","article-title":"Review article: pruritus in cholestatic and other liver diseases.","volume":"17","author":"Mela","year":"2003","journal-title":"Aliment Pharmacol Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clinre.2010.10.007","article-title":"Pathophysiology and current management of pruritus in liver disease.","volume":"35","author":"Kremer","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/s0016-5085(19)31870-0","article-title":"Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus.","volume":"73","author":"Ghent","year":"1977","journal-title":"Gastroenterology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia.","volume":"123","author":"Alemi","year":"2013","journal-title":"J Clin Invest."},{"key":"B8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/gut.13.3.201","article-title":"Serum bile acids in primary biliary cirrhosis.","volume":"13","author":"Murphy","year":"1972","journal-title":"Gut."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1001\/archinte.159.22.2647","article-title":"The continuing importance of bile acids in liver and intestinal disease.","volume":"159","author":"Hofmann","year":"1999","journal-title":"Arch Intern Med."},{"key":"B10","article-title":"Chemistry and biology of bile acids.","volume":"87","author":"Mukhopadhyay","year":"2004","journal-title":"Curr Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1152\/physrev.00049.2019","article-title":"Molecular physiology of bile acid signaling in health, disease, and aging.","volume":"101","author":"Perino","year":"2021","journal-title":"Physiol Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.bbadis.2018.08.001","article-title":"Bile acids and glucocorticoid metabolism in health and disease.","volume":"1865","author":"Theiler-Schwetz","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000282091","article-title":"Bile acids as regulators of hepatic lipid and glucose metabolism.","volume":"28","author":"Trauner","year":"2010","journal-title":"Dig Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/s0022-2275(20)38479-0","article-title":"Similarity of unusual bile acids in human umbilical cord blood and amniotic fluid from newborns and in sera and urine from adult patients with cholestatic liver diseases.","volume":"29","author":"Shoda","year":"1988","journal-title":"J Lipid Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/s0022-2275(20)42749-x","article-title":"Bile acid metabolism in early life: studies of amniotic fluid.","volume":"31","author":"Nakagawa","year":"1990","journal-title":"J Lipid Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: regulation of synthesis.","volume":"50","author":"Chiang","year":"2009","journal-title":"J Lipid Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00018-008-7568-6","article-title":"Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics.","volume":"65","author":"Hofmann","year":"2008","journal-title":"Cell Mol Life Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor.","volume":"284","author":"Parks","year":"1999","journal-title":"Science (80)."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bite acids.","volume":"284","author":"Makishima","year":"1999","journal-title":"Science (80)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"29749","DOI":"10.1074\/jbc.274.42.29749","article-title":"Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor\/9-cis- retinoic acid receptor heterodimer.","volume":"274","author":"Grobert","year":"1999","journal-title":"J Biol Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"G476","DOI":"10.1152\/ajpgi.00430.2005","article-title":"The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-\u03b1 and -\u03b2 genes.","volume":"290","author":"Landrier","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1152\/physiologyonline.1999.14.1.24","article-title":"Bile acids: the good, the bad, and the ugly.","volume":"14","author":"Hofmann","year":"1999","journal-title":"News Physiol Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0016-5085(69)80004-1","article-title":"Conjugated and unconjugated serum bile acid levels in patients with hepatobiliary diseases.","volume":"56","author":"Makino","year":"1969","journal-title":"Gastroenterology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"27703","DOI":"10.1074\/jbc.M302128200","article-title":"Farnesoid X receptor regulates bile acid-amino acid conjugation.","volume":"278","author":"Pircher","year":"2003","journal-title":"J Biol Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbior.2012.09.010","article-title":"Structure-function relationships of autotaxin, a secreted lysophospholipase D.","volume":"53","author":"Hausmann","year":"2013","journal-title":"Adv Biol Regul."},{"key":"B26","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/MPG.0000000000001044","article-title":"Serum autotaxin activity correlates with pruritus in pediatric cholestatic disorders.","volume":"62","author":"Kremer","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","article-title":"Lysophosphatidic acid is a potential mediator of cholestatic pruritus.","volume":"139","author":"Kremer","year":"2010","journal-title":"Gastroenterology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MPG.0000000000001334","article-title":"Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American society for pediatric gastroenterology, hepatology, and nutrition and the European society for pediatric gastroenterology, hepatology, and nutriti.","volume":"64","author":"Fawaz","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2340\/00015555-2433","article-title":"Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch.","volume":"96","author":"Reich","year":"2016","journal-title":"Acta Derm Venereol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cca.2016.11.014","article-title":"Bile acid preparation and comprehensive analysis by high performance liquid chromatography\u2013high-resolution mass spectrometry.","volume":"464","author":"Amplatz","year":"2017","journal-title":"Clin Chim Acta."},{"key":"B31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jchromb.2012.05.015","article-title":"Bile acid profiling in human biological samples: comparison of extraction procedures and application to normal and cholestatic patients.","volume":"899","author":"Humbert","year":"2012","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/0016-5085(90)90027-X","article-title":"Rifampin relieves pruritus in children with cholestatic liver disease.","volume":"98","author":"Cynamon","year":"1990","journal-title":"Gastroenterology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/S12098-007-0044-8","article-title":"Safety and efficacy of rifampicin in children with cholestatic pruritus.","volume":"74","author":"El-Karaksy","year":"2007","journal-title":"Indian J Pediatr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis.","volume":"336","author":"Lindor","year":"1997","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","article-title":"Natural history of pruritus in primary biliary cirrhosis.","volume":"1","author":"Talwalkar","year":"2003","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.","volume":"16","author":"Beuers","year":"1992","journal-title":"Hepatology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/MPG.0b013e318297e384","article-title":"Management of cholestatic pruritus in paediatric patients with alagille syndrome: the king\u2019s college hospital experience.","volume":"57","author":"Kronsten","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial.","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1525-1470.2008.00699.x","article-title":"The use of naltrexone in the management of severe generalized pruritus in biliary atresia: report of a case.","volume":"25","author":"Chang","year":"2008","journal-title":"Pediatr Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/MPG.0b013e3181eb5ac0","article-title":"Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children.","volume":"51","author":"Zellos","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/MPG.0000000000001385","article-title":"Sertraline as an additional treatment for cholestatic pruritus in children.","volume":"64","author":"Th\u00e9baut","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101751","article-title":"Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study.","volume":"45","author":"Baumann","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clinre.2017.08.007","article-title":"An update on the physiopathology and therapeutic management of cholestatic pruritus in children.","volume":"42","author":"Th\u00e9baut","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jhep.2012.04.017","article-title":"Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2.","volume":"57","author":"Gonzales","year":"2012","journal-title":"J Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/J.DLD.2011.10.025","article-title":"Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study.","volume":"44","author":"Trottier","year":"2012","journal-title":"Dig Liver Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1042\/bj1540507","article-title":"Identification of bile acids in the serum and urine in cholestasis. Evidence for 6alpha-hydroxylation of bile acids in man.","volume":"154","author":"Summerfield","year":"1976","journal-title":"Biochem J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"B48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41390-018-0007-y","article-title":"Neonatal sepsis leads to early rise of rare serum bile acid tauro-omega-muricholic acid (TOMCA).","volume":"84","author":"Z\u00f6hrer","year":"2018","journal-title":"Pediatr Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"39436","DOI":"10.1074\/jbc.M205623200","article-title":"Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase.","volume":"277","author":"Tokumura","year":"2002","journal-title":"J Biol Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions.","volume":"56","author":"Kremer","year":"2012","journal-title":"Hepatology."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.903360\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T07:38:29Z","timestamp":1652254709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.903360\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":50,"alternative-id":["10.3389\/fped.2022.903360"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.903360","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"article-number":"903360"}}